Actively Recruiting
Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes
Led by Peking University First Hospital · Updated on 2025-07-30
312
Participants Needed
1
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic postsurgical pain (CPSP) refers to pain that occurs or increases after surgery and lasts longer than 3 months. Severe acute postoperative pain is one of the major risk factors of CPSP. Spinal correction surgery is associated with severe pain due to large trauma and long duration. Ketamine and esketamine are N-methyl-D-aspartate receptor antagonists; they have antihyperalgesic effects and may reduce CPSP. Dexmedetomidine is an alpha 2-adrenoceptor agonist with sedative, anxiolytic, and analgesic effect; it is frequently used as an adjuvant to postoperative analgesia. In a previous trial of 200 patients after scoliosis correction surgery, mini-dose esketamine-dexmedetomidine in combination with opioids significantly improved analgesia and sleep quality but did not reduce CPSP. The authors speculate that increasing esketamine dose in the combination may further improve analgesia and, therefore, reduce the occurrence of CPSP.
CONDITIONS
Official Title
Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 6518 years and body weight6540 kg
- Scheduled to undergo scoliosis correction with pedicle screw fixation
- Required patient-controlled intravenous analgesia (PCIA) after surgery
You will not qualify if you...
- Preoperative sick sinus syndrome, severe sinus bradycardia (heart rate <50 beats per minute), atrioventricular block grade II or above without pacemaker, congenital heart disease, arrhythmia, or other serious cardiovascular diseases with a New York Heart Association class 653III
- Patients with moderate or severe obstructive sleep apnea diagnosed preoperatively or according to the STOP-Bang score
- History of hyperthyroidism or pheochromocytoma
- History of schizophrenia, epilepsy, myasthenia gravis
- Severe liver dysfunction (Child-Pugh grade C), severe renal dysfunction (preoperative dialysis), or American Society of Anaesthesiologists grade 654
- Barrier in communication
- Other conditions that were considered unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
D
Dong-Xin Wang, MD, PhD
CONTACT
F
Fan Cui, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here